Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC P S O P versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC P S O P versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
CHLOROPTIC-P S.O.P. vs NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroptic-P S.O.P. contains prednisolone acetate and chloramphenicol. Prednisolone acetate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Chloramphenicol is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
Adults: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily, or more frequently as needed. Not for injection.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (systemic); prolonged to 21-24 hours in severe hepatic impairment. Clinical context: short half-life supports 2-3 times daily dosing.
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Renal: 50-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites; small amount via lacrimal drainage after ophthalmic administration.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic